Effects of sustained-release lanreotide on hemodynamics in rats with portal vein stenosis.
OBJECTIVE
Somatostatin and its analogue have been shown to provide beneficial effects in the management of portal hypertension and hyperdynamic circulation. The current study was undertaken to evaluate the effects of lanreotide, a sustained-release somatostatin analogue, on hemodynamics in rats with portal hypertension.


METHODS
Immediately after portal vein stenosis, rats were randomly assigned to receive vehicle or a single intramuscular injection of lanreotide 10 mg/kg. Hemodynamic measurements (radioactive microsphere technique) with portal systemic shunts determinations were performed on the 4th and 8th day after surgery, respectively.


RESULTS
On the 4th day after surgery, rats treated with lanreotide had significantly lower cardiac index and higher systemic vascular resistance than rats treated with vehicle, while these values were no different on the 8th day after portal vein stenosis. In contrast, the elevation of portal pressure, portal tributary blood flow, and splanchnic fraction of cardiac output had ameliorated following lanreotide administration associated with an increase in splanchnic arterial resistance. Portal systemic shunts were lower in rats receiving lanreotide than in rats receiving vehicle.


CONCLUSIONS
The current study showed that a single injection of sustained-release lanreotide in rats with portal vein stenosis delayed the development of peripheral arterial vasodilatation and hyperdynamic circulation, while it modified the evolution of portal hypertension and splanchnic hyperemia. This treatment also prevents, in part, the development of portal systemic shunts in rats with portal vein stenosis.
Lin
H C
HC
Department of Medicine, Taipei Veterans General Hospital and National Yang-Ming University School of Medicine, Taiwan. hclin@vghtpe.gov.tw
Huang
Y T
YT
Wu
H L
HL
Lee
W C
WC
Hou
M C
MC
Lee
F Y
FY
Chang
F Y
FY
Lee
S D
SD
D000818:Animals; D003251:Constriction, Pathologic; D003692:Delayed-Action Preparations; D004353:Drug Evaluation, Preclinical; D005934:Glucagon / Q000097:blood; D006439:Hemodynamics / Q000187:drug effects*; D007273:Injections, Intramuscular; D008297:Male; D008863:Microspheres; D010456:Peptides, Cyclic / Q000627:therapeutic use*; D011169:Portal Vein / Q000187:drug effects*; D051381:Rats; D017207:Rats, Sprague-Dawley; D013004:Somatostatin / Q000031:analogs & derivatives* / Q000627:therapeutic use
D003692:Delayed-Action Preparations; D010456:Peptides, Cyclic; C060347:lanreotide; D013004:Somatostatin; D005934:Glucagon